DeepMed Research

North Eastern German Society of Gynaecological Oncology

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Phase 2

Recruiting

Conditions: Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Clear Cell Carcinoma
Ovarian Cancer

Interventions: Drug: 6 cycles chemotherapy
Drug: 3 cycles chemotherapy instead of 6 cycles chemotherapy

First Posted Date: 2022-07-15

Last Posted Date: 2025-04-27

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 640

Registration Number: NCT05460000

Locations: 🇮🇹
Azienda USL IRCCS Di Reggio Emilia, Reggio Emilia, Italy
🇧🇪
Cliniques Universitaires St. Luc, Brussels, Belgium
🇧🇪
Jessa ziekenhuis, Hasselt, Belgium

and more 43 locations

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Low Grade Serous Carcinoma
Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2020-10-05

Last Posted Date: 2025-05-23

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 33

Registration Number: NCT04575961

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇩🇪
Kliniken Essen Mitte, Essen, Germany

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Phase 3

Completed

Conditions: Clear Cell Carcinoma
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Placebos
Drug: Rucaparib

First Posted Date: 2020-01-13

Last Posted Date: 2024-11-15

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 42

Registration Number: NCT04227522

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇩🇪
Städtisches Klinikum Dessau, Dessau, Germany
🇩🇪
Städtisches Krankenhaus Kiel, Kiel, Germany

and more 14 locations

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Active, not recruiting

Conditions: Primary Invasive Breast Cancer
Estrogen Receptor Positive Tumor
Human Epidermal Growth Factor Receptor 2 Negative Tumor

Interventions: Other: Observation

First Posted Date: 2018-04-20

Last Posted Date: 2024-11-15

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 1191

Registration Number: NCT03503799

Locations: 🇩🇪
ANregiomed Ansbach, Ansbach, Germany
🇩🇪
Krankenhaus St. Marienstift, Magdeburg, Germany
🇩🇪
Frauenklinik der Technischen Universität München, München, Bayern, Germany

and more 37 locations

QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Phase 4

Terminated

Conditions: Recurrent Ovarian Carcinoma
Quality of Life
Ovarian Cancer

Interventions: Drug: Trabectidin (Yondelis)

First Posted Date: 2017-05-24

Last Posted Date: 2025-03-20

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 89

Registration Number: NCT03164980

Locations: 🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪
Sankt Gertrauden-Krankenhaus, Berlin, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany

and more 18 locations

Pazopanib Vs. Pazopanib Plus Gemcitabine

Phase 2

Active, not recruiting

Conditions: Leiomyosarcoma or Carcinosarcoma

Interventions: Drug: Pazopanib
Drug: Pazopanib plus Gemcitabine

First Posted Date: 2014-07-30

Last Posted Date: 2024-11-15

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 58

Registration Number: NCT02203760

Locations: 🇩🇪
Universitätsklinikum Bonn, Bonn, Germany
🇩🇪
Helios Klinikum Berlin-Buch, Klinik für Onkologie und Paliativmedizin, Berlin, Germany
🇩🇪
Helios Klinikum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum, Bad Saarow, Germany

and more 6 locations

Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Cyclophosphamide, Epirubicin, Paclitaxel
Drug: Epirubicin, Paclitaxel, Filgrastim

First Posted Date: 2008-04-29

Last Posted Date: 2010-07-29

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 1034

Registration Number: NCT00668616

Locations: 🇩🇪
Oskar-Ziethen-Krankenhaus, Berlin, Germany

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Topotecan

First Posted Date: 2007-02-21

Last Posted Date: 2016-09-22

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 550

Registration Number: NCT00437307

Locations: 🇩🇪
Charité Campus Virchow Klinikum, Berlin, Germany

Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2006-04-11

Last Posted Date: 2006-04-11

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 450

Registration Number: NCT00312988

Locations: 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Caelyx

First Posted Date: 2005-09-15

Last Posted Date: 2024-12-16

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 77

Registration Number: NCT00170573

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy